Sulphasalazine and mesalazine: Serious adverse reactions reevaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines (multiple letters) [1]

Gut

Volumn 52, Issue 10, 2003, Pages 1530-1531

  Logan, R F ^a,c   Van Staa, T P ^b   Langman, M J S ^d,e   Ransford, R A J ^d  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b PROCTER AND GAMBLE COMPANY   (United States)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^e UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; MESALAZINE; SALAZOSULFAPYRIDINE;

CROHN DISEASE; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GENERAL PRACTICE; HUMAN; INCIDENCE; INTERSTITIAL NEPHRITIS; LETTER; MEDICAL PRACTICE; NEPHROTOXICITY; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; STATISTICAL SIGNIFICANCE; UNITED KINGDOM; VALIDATION PROCESS;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DATA INTERPRETATION, STATISTICAL; DATABASES, FACTUAL; HUMANS; KIDNEY DISEASES; MESALAMINE; SULFASALAZINE;

EID: 0141869034     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.52.10.1530     Document Type: Letter

References (0)